

Reference

Aaron L, Saadoun D, Calatroni I et al. (2004): Tuberculosis in HIV-Infected Patients: A Comprehensive Review.” Clin Microbio Infect; 10 (5): 388–98.

Abd El Hamid R (2007): A thesis summated in Ain Shams University (Rapid Detection of multidrug resistant mycobacterium tuberculosis using mycobacteria growth indication tube (MGIT) system.

Alcaide F (1997): The role of EMB in natural and acquired resistance to Ethambutol in mycobacteria. Antimicrobial Agents. Chemother, 41: 2270-3.

Alito A, Morcillo N, Scipioni S et al. (1999): The IS6110 restriction fragment length polymorphism in particular multidrug-resistant Mycobacterium tuberculosis strains may evolve too fast for reliable use in outbreak investigation. J Clin Microbiol; 37 (3):788-91.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America(2003): treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.

American Thoracic Society, Center for Disease Control (1986): Treatment of tuberculosis and tuberculous infection in adults and children. Am. Rev. Respir. Dis; 134: 355.

Androile VT (1990): Quinolones in: Modnell GI, Douglas RG and Bennett JE (Eds) Principles and practices of infectious diseases. Churchill Livingstone, Inc. New York, P: 334-345.

Angeby KA, Klintz L and Hoffner SE (2002): Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol; 40 (2): 553-555.

Appel GB, Neu HC(1977): The nephrotoxicity of antimicrobial agents [second of three parts]. N Engl J Med;296:722-728.

Banaiee N, Bobadilla-Del-Valle M, Bardarov S et al. (2001): Luciferase reporter mycobacteriophages for detection, identification, and antibiotic susceptibility testing of Mycobacterium tuberculosis in Mexico. J Clin Microbiol; 39 (11): 3883-8.

Bass JB, Farer LS, Hopewell PC, et al.(1990): Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis; 142 (3):725-735.

Bayona J, Chavez-Pachas AM, Palacios E et al. (2003): Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuber Lung Dis; 7 (12 Suppl 3):S501– 509.

Beck-Sange, dooleySW, Hutton MD.(1992):Hospital outbreak of multi-drug resistance mycobacterium tuberculosis infection; factors in transmission to staff and HIV-infected patients.JAMA;269:1280-6.

Bemer P, Palicova F, Rusch-Gerdes S et al. (2002): Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol; 40 (1): 150-4.

Berning SE, Peloquin CA. (1998): Antimycobacterial agents: Isoniazid. In: Antimicrobial Therapy and Vaccines, Yu, V, Merigan, T, Barriere, S (Eds), Williams and Wilkins, Baltimore 1998.

Blaschke T and Skinner M (1996): The clinical pharmacokinetics of Rifabutin. Clin Infect Dis, 22: 515-521.

Blower SM and Chou T (2004): Modeling the emergence of the “hot zones”: tuberculosis and the amplification dynamics of drug resistance. Nat Med; 10 (10):1111–6.

Body BA, Warren NG, Spicer A et al. (1990):Caught from Kamal (2006) Thesis submitted in Ain Shams University (multiple drug

resistance tuberculosis in Abbasia Chest Hospital from January 2005 to December 2005).

Botha FJH, Sirgel FA, Parkin DP, et al. (1996): The early bactericidal activity of ethambutol, pyrazinamide, and the fixed combination of isoniazid, rifampicin, and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J; 86:155-158.

Brodie D and Schluger NW (2005): The diagnosis of tuberculosis. Clin Chest Med 26: 247-271.

Brunello F, Favari F, and Fontana R (1999): Comparison of MB/BacT and BACTEC 460 TB system for recovery of mycobacteria from various clinical samples. Journal of Clinical Microbiology, April 37(4): 1206-1209.

Bulter WB, Jost KC and Kilbum JO (1991): Identification of mycobacteria by high-performance liquid chromatography. J Clin Microbiol; 29: 2468.

Byrd, CB, Nelson, et al. (1972): Isoniazid toxicity. A prospective study in secondary chemoprophylaxis. JAMA 1972; 220:1471.

Caviedes L, Lee TS, Gilman RH, Sheen P et al. (2000): The Tuberculosis Working Group in Peru. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J Clin Microbiol; 38 (3): 1203-1208.

Caviedes L, Delgado J and Gilman RH (2002): Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J Clin Microbiol; (5):1873-4.

Centers for Disease Control and Prevention (1998): Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations.. SO - MMWR Recomm Rep 1998 Oct 30;47(RR-20):1-58.

Centers for Disease Control and Prevention(2006): Reported Tuberculosis in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, CDC, September 2006.

Centers for Disease Control (1993): Initial therapy in the era of multi-drug resistance, recommendation of advisory council for the elimination of tuberculosis MMWR; 42(RR-7):1.

Centers for Disease Control and Prevention(2009) . Reported Tuberculosis in the United States, 2008 . Atlanta, GA: U .S . Department of Health and Human Services, CDC, September 2009

Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW, Mitchison DA (1992): The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis;73:33--38.

Chan ED, Heifets L and Iseman MD (2000):Imunologic diagnosis of tuberculosis: a review Tubercle and Lung Disease ;80(3): 131-140.

Chang KC, Leung CC, Yew WW, et al. (2008):Hepatotoxicity of pyrazinamide: cohort and case-control analyses.Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6. Epub 2008 Apr 3.

Chaulet P and Zidouni N. (1996): Failures in tuberculosis chemotherapy. In “Tuberculosis”, edited by Gangadharam PRJ

Cheng AF, Yew WW, Chan EW et al. (2004): Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother; 48 (2), 596–601.

Coban AY, Birinci A, Ekinci B and Durupinar B (2004): Caught from Abd El Hamid, (2006) Thesis submitted in Ain Shams University (Rapid detection of multidrug resistant mycobacterium tuberculosis using mycobacteria growth indication tube (MGIT system).

Colditz GA, Brewer TF, Berkey CS et al. (1994): Efficacy of BCG vaccine in the prevention of TB: meta-analysis of the published literature. JAMA 271: 698-702.

Condos R, Rom WN, Schulger NW (1997): Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol, *Lancet*; 349: 1513-5.

Cox H, Kebede Y, Allamuratova S et al. (2006): Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance. *PLoS Med*, 3(10): e384.

Crawford TJ (1995): Caught from Kamal (2006) Thesis submitted in Ain Shams University (multiple drug resistance tuberculosis in Abbasia Chest Hospital from January 2005 to December 2005).

Crofton J, Chaulet P and Maher D (1997): Guidelines for the Management of Drug-resistant Tuberculosis, 1st edn. World Health Organization, Geneva, Switzerland. (WHO/TB/ 96.210 Rev1).

Crowhe A.J., Sbarbao J.A. and Judson F.N. (1986): Inhibition by pyrazinamide of tubercle bacilli within cultured macrophages. *Am. Rev. Respir. Dis.*; 134: 1052.

Cruciani M, Scarparo C, Malena M et al. (2004): Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of BACTEC 460 TB, with or without solid media, For detection of Mycobacteria. *J of Clin Microbiol* 42(5): 2321-2325.

Davies P.D.O. and Grange J.M. (2001): Factors affecting susceptibility and resistance to tuberculosis. *Thorax*; 56(Suppl.II): ii23-ii29.

David S (1999): Tuberculosis and nontuberculous mycobacterial infections WB. Saunders Company Philadelphia, Pennsylvania 19-6. 4th ed Chap. 6, p. 75.

Diacon AH, van de Wal BW Wyser C et al. (2003): University of Stellenbosch Medical School Tyberberg Hospital, Cape Town, South Africa: Diagnostic tools in tuberculous pleurisy, a direct comparative study.

Di Perri G and Bonora S (2004): Which agents should we use for the treatment of multidrug-resistant *Mycobacterium tuberculosis*? *J Antimicrob Chemo*; 54 (3): 593–602.

Dooley SW, Jarvis WR, Martone WJ and Snyder DE (1992): Multi-Drug resistant tuberculosis [editorial]. *Ann Intern Med*; 117:257-8.

Dorman SE, Johnson JL, Goldberg S, et al. (2009): Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. *Am J Respir Crit Care Med.* 2009 Aug 1;180(3):273-80. Epub 2009 Apr 30.

Dukes CS, Sugarman J, Cegielsk JP et al. (1993): Severe cutaneous hypersensitivity reactions in patients with HIV infection in Tanzania. *Trop Geogr Med* 44: 308-311.

El-Gazzar AG, Abd El-Rahman S, Rifaat MM (1998): molecular genetics of drug resistance of mycobacterium tuberculosis. *Egypt J Chest and TB*, 47:9-18.

Ellner J, Hinman S and Dooley SW (1993): Tuberculosis symposium: emerging problems and promise *J Infect Dis* 158: 537-555.

Esmat M., El-Ray F, Sawi M.S., Metwally S., El-Sawi M.S., Metwally S., El-Saad F.A. and Oaf F. (1988): Study of primary resistance of tubercle bacilli in patients of Mehlla Chest Hospital. *Egypt J. Chest Dis. & Tuber.*; 35: 194-210.

Espinal MA (2003): The global situation of MDR-TB. *Tuberculosis. (Edinb.)*; 83 (1-3): 44–51.

Espinal MA, Dye C, Raviglione M and Kochi A (1999): Rational 'DOTS plus' for the control of MDR-TB. *Int J Tuberc Lung Dis*; 3(7):561-3.

Etemadi A, Farid R, Stanford JL (1992): Immunotherapy for drug-resistant tuberculosis. *Lancet*; 340: 1360-1.

Fawzy M (2005): Resistance to INH and Rifampicin in pulmonary tuberculous patients. Thesis submitted for partial fulfillment of master degree in chest disease and tuberculosis. Ain Shams University.

Fishman AP, Elias JA, Fishman JA et al. (1998): Microbiology of the mycobacteria. *Pulmonary Disease*. 2: 2443.

Forbes AB, Sahm FD and Weissfeld SA (1998): Molecular methods for microbial identifications chapter 14 page 188. laboratory methods for detection of antibacterial resistance chapter 18 page 250-70 laboratory strategies for antimicrobial susceptibility testing chapter 19 page 274-80. mycobacteria chapter 50 page 715-41. *Diagnostic microbiology by Bailey and Scott's Tenth edition.*

Frieden TR and Khatri GR (2002): Multi-drug resistant tuberculosis. In: Narain JP (eds). Tuberculosis epidemiology and control. (WHO/SEA/TB/ 248). New Delhi: World Health Organization Regional Office for South-East Asia; p.105-15.

Gangadharam PR, Geeta N, Hsu YY, Wise DL. (1999): Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. *Int J Tuberc Lung Dis*;3:515--520.

George WG (2002): The global fund to fight tuberculosis. Global programme on tuberculosis. The current global situation of TB in Egypt. *Wkly Epidemiol Rec* 69: 161-165.

Girling DJ. (1984): The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. *Tubercle*;65:1--4..

Goble M. (1986): Drug resistant tuberculosis. *Semin Respir Infect*; 1:220.

Goble M, Iseman MD, Madsen LA et al. (1993): Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *N Engl J Med*; 328 (8): 527–532.

Goldfarb D and Samin L (1996): Tuberculosis of the genitourinary tract. In: Rom WN, Garay S (eds). Tuberculosis. New York: Little Brown; 609–22.

Goldstein D, Hertzog P, Tomkinson E et al. (1998): Administration of imiquimod, an interferon inducer, in a symptomatic human immunodeficiency virus infected persons to determine safety and biologic response modification *J Infect Dis*; 178: 858-60.

Greco S, Girardi E, Masciangelo R et al. (2004): Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: A meta analysis. *Int J Tuberc Lung Dis* 8: 622-3.

Grosset J. (1980): Bacteriologic basis of short-course chemotherapy for tuberculosis. *Clin ChestMed* 1980; 1: 231.

HAAS W.D. and Des Prez M.R. (1995): Current treatment and management, tuberculosis clinical management and new challenges. Rossman DM, MacGregor RRM. Graw Hill; 187-205.

Hafner R, Cohn JA, Wright DJ, et al. (1997): Early bactericidal activity of isoniazid in pulmonary tuberculosis. *Am J Respir Crit Care Med*;156:918--923.

Harries AD and Maher D (1996): TB/HIV: a clinical manual (WHO/TB/96.200:38). Geneva: WHO.

Heifets L, Linder T, Sanchez T et al. (2000): Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for mycobacterium tuberculosis isolation from specimens. *J of clin Microbiol* 38(3): 1227-1230.

Hesseling AC, Schaaf HS, Gie RP et al. (2002): A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. *Int J Tuberc Lung Dis*; 6: 1038–45.

Honore N and Cole ST (1994): Streptomycin resistance in mycobacteria. *Antimicrob Agents Chemother*; 38: 238-42.

Huang TS, Chen CH, Lee SS et al. (2001): Comparison of BACTEC MGIT 960 and BACTEC 460 TB system for detection of mycobacteria in Clinical specimens. *Annals of Clinical and Laboratory Science* 31(3): 279-283.

Huebner RE, Schein MF and Bass JB (1993): The tuberculin skin test. *Clin Infect Dis*; 17 (6): 968–75.

Hussein R, Moustafa R , Lila El K, et al. (2000): Isoniazid (INH) AND Rifampicin (RIF) resistance in patient with pulmonary tuberculosis with special reference to atypical mycobacterial infection. *Egyptian Journal of Chest*, 49-2.

Ian A Campbell, Oumou Bah-Sow(2006): Pulmonary tuberculosis: diagnosis and treatment *BMJ* 332.

Inderlied CB and Salfinger M (1995): Antimicrobial agents and susceptibility tests: Mycobacteria. In: Murray PR, Jobran E et al. (eds), P 1385-1401. *Manual of clinical microbiology* 6th ed. American Society for Microbiology Washington DC.

Iseman MD (1993): Treatment of multidrug-resistant tuberculosis. *N Engl J Med*; 329 (11): 784–791.

Iseman MD (2000): A clinician's guide to tuberculosis. Philadelphia: Lippincott Williams and Wilkins.

Isenberg HD, D'Amato RF, Helfets L et al. (1991): Collaborative feasibility study of a biphasic system (Roche Septi-Check AFB) for rapid detection and isolation of mycobacteria. J Clin Microbiol 39: 1719.

J.Assoc(2006): API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis Pub Med - indexed for MEDLINE

Jenner PJ, Ellard GA, Allan WG, Singh D, Girling DJ, Nunn AJ. (1981): Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. Tubercle;62:175--179.

Jindani A, Aber VR, Edwards EA, Mitchison DA. (1980): The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis;121:939--949.

Johansen IS, Thomsen V, Marjamaki M et al. (2004): Rapid, automated, non radiometric susceptibility testing of mycobacterium tuberculosis complex to four drugs used in standard short-course line chemotherapy. Diagn Microbiol Infect Dis; 50 (2):103-7.

Johansen IS (2006): Rapid diagnoses of mycobacterial diseases, and their implication on clinical management. Dan Med Bul; 53 (1):28-45.

Kartaloglu Z, Okutan O, Bozkanat E et al. (2006): The course of serum adenosine deaminase levels in patients with pulmonary TB. <http://journals-index.compemicus.com/abstracted.php?1cid=4629>.

Kent BD and Kubica GP (1985): Caught from Kamal (2006) Thesis submitted in Ain Shams University (multiple drug resistance tuberculosis in Abbasia Chest Hospital from January 2005 to December 2005).

Kim SJ (2005): Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J; 25 (3): 564–569.

Kir A, Tahaoglu K, Okur E and Hatipoglu T (1997): Caught from Kamal (2006) Thesis submitted in Ain Shams University (multiple drug resistance tuberculosis in Abbasia Chest Hospital from January 2005 to December 2005).

Kochi A, Vareldzis B and Styblo K (1993): Multi-Drug resistant tuberculosis and control. *Res Microbiol*; 144 (2):104-10.

Koumbaniou C; Nicopoulos C; Vassiliou M et al. (1998): Is pyrazinamide really the third drug of choice in the treatment of tuberculosis? *Int J Tuberc Lung Dis* 1998 Aug;2(8):675-8.

Kramer FT, Modelewsky AR, Walinay AR et al. (1990): Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. *Am. J. Med*; 89 (4):451–456.

Lambregts-van Weezenbeek, Veen J, Jansen HM, Veen J et al. (1998): Origin and management of primary and acquired drug-resistant tuberculosis in the Netherlands: the truth behind the rates. *Int J Tuberc Lung Dis*; 2 (4): 296–302.

Lee KS, Song KS, Lim TH, Kim PN et al. (1993): Adult onset pulmonary tuberculosis: findings on chest radiograph and CT scans. *AJR Am Roentgenol*; 160 (4):753-8.

Lee E and Holzman RS (2002): Evolution and current use of the tuberculin test. *Clin Infect Dis*; 34 (3): 365–70.

Leithch AG (1996): Pulmonary tuberculosis, clinical features, Crofton; Chapter 17 page 522-524.

Letvin NL, Bloom BR, Hoffman SL (2001): Prospects for vaccines to protect against AIDs, TB, and Malaria. *JAMA* 285: 606-11.

Lobue PA; Moser KS Am J (2003): *Respir Crit Care Med* 2003 Aug 15;168(4):443-7. Epub May 13.

Loddenkemper R (2000): The need for antituberculosis drug, resistance surveillance in Europe. *Eur Respir J*; 16(2): 195-196.

Loddenkemper R, Sagebiel D and Brendel A (2002): Strategies against multidrug-resistant tuberculosis. *Eur Respir J*; 20:66S-77S.

Long R (2000): Editor Canadian TB Standards 5 th ed. Ottawa: Canadian Lung association, Health Canada; 2000.

Madkour M (2004): Millitary/Disseminated Tuberculosis. In: Madkour M (ed). Tuberculosis. Springer-Verlag Berlin Heidelberg; pp273-300.

Mahmoudi A and Iseman MD (1993): Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA; 270 (1):65-8.

Mak A; Thomas A; Del Granado M; Zaleskis R; Mouzafarova N; Menzies (2008):Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens D Am J Respir Crit Care Med. 2008 Aug 1;178(3):306-12. Epub 2008 May 29.

Manaloff, Tan F, Sbarbaro JA and Iseman MD (1990): Community based short course treatment of pulmonary tuberculosis in developing nation. Am Rev Respir Dis 142: 1301.

Mandell GI and Petri GR (1996): Drugs used in the chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy. Chapter 48, P 1155-1171. In: Goodman and Gilman's Pharmacological Basis of therapeutics, 9th ed. McGraw Hill Inc.

Martinez E, Collazos J, Mayo J(1999) Hypersensitivity reactions to rifampin. Medicine (Baltimore) 1999;78:361--369.

Masoud H. M., Sharaf EL-Din M.M. and Abou Issa M.H. (1989):Initial drug resistance among newly diagnosed cases with pulmonary tuberculosis. Egypt J. Chest &Tuber.; 36(2): 177-186.

Mazouni L, Zidouni N, Boulahbal F, Chaulet P(1992):Treatment of failure and relapse cases of pulmonary tuberculosis within a national

programme based on short- course chemotherapy (preliminary report).
TSRU, Progress Report, 1992, Vol. 1: 36-42.

Mdlui K, Slayden RA and Zhu YQ (1998): Inhibition of a mycobacterium tuberculosis beta-ketoacyl ACP synthase by Isonazid. Science, 280: 1607-10.

Meier A, Sandr P and Schaper KJ (1996): Correlation of molecular resistance levels in streptomycin resistant mycobacterium tuberculosis. Antimiorbial Agent Chemother, 40: 2452-4.

Mendez AP, Ravigilon MC and Laszlo A (1998): Global surveillance for antituberculosis drug resistance. N Surg J Med 338: 1641-9.

Menzies, D, Doherty, TM(2006):Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield's Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), New York, Informa Healthcare USA. 2006:215-63

Middlebrook G, Reggiardo Z and Tigertt WD (1977): Automatatable radiometric detection of growth of mycobacterium tuberculosis in selective media. Am Rev Respir Dis 115; 1066-1069.

Migliori GB, Centis R, Fattorini L et al. (2004): Mycobacterium tuberculosis complex drug resistance in Italy. Emerg Infect Dis; 10 (4):752-3.

Mitchison D.A. (1984): Drug resistance in mycobacteria. Br. Med. Bull.; 40: 84.

Mitchison D.A. and Nunn A.J. (1986): Influence of initial drug resistance on the response to short course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis.; 133: 423.

Mitnick C,Bayona J,Placacios E, (2003):community-based therapy for multi-drug resistant tuberculosis in Lima, Peru.n Engl jMed ;348:119-128.

Mitnick CD, Shin SS, Seung KJ, et al. (2008) : Comprehensive treatment of extensively drug-resistant tuberculosis N Engl J Med. 2008 Aug 7;359(6):563-74.

Mohamed A; Ibrahim A; Taher A(2009): a thesis Submitted in Ain Shames University :Evaluation of Outcome of Multi-Drug Resistant Antituberculous Treatment in Abbassia Chest Hospital between July 2006 to June 2008

Mohamed E (2002): Study of the problem of drug-resistance of TB among patients with pulmonary tuberculosis in Ismailia and Suez Canal Hospital. Thesis submitted for partial fulfillment of master degree in chest diseases done in Suez Canal University.

Mona A; M.Mansour; T.Safwat(2005): a thesis Submitted in Ain Shames University: Resistance to INH and rifampicins in pulmonary tuberculous patient)

Moore DA, Evans CA, Gilman RH et al. (2006): Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med; 355 (15):1539-50.

Morsi MG, Youssef RM and Khalil YM (1997): Evaluation of enzyme-linked immunosorbent assay (ELISA) in serodiagnosis of pulmonary tuberculosis. Eastern Mediterranean Health Journal; 3 (3):480-492.

Moulding T, Dutt AK, Reichman LB (1995): Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med;122:951--954.

Mukherjee JS, Rich ML Socci AR, et al. (2004): Programmes and principals in treatment of multi-drug resistant tuberculosis. Lancet 2004; 363(9407): 474-81.

Muzaffar R, Batool S, Aziz F et al. (2002): Evaluation of the fast plaque TB assay for direct detection of mycobacterium TB in sputum specimens in Pakistan. Int J Tuberc Lung Dis 6(7): 635-640.

Nahid P, Pai M, and Howpwell PC (2006): Advances in the diagnosis and treatment of tuberculosis. The Proceeding of the American Thoracic Society 103-110.

National institute for health and clinical excellence (2006): Introduction1 (NICE guideline – tuberculosis respiratory TB).

National Institute of Allergy and Infectious Diseases(2007):Promising New TB Drug Given Special Status By US And European Regulators Science Daily.

National TB program (NTP) (2005): National tuberculosis control programme tuberculosis guide for physicians 2005.

National TB program (NTP) (2005): The national TB control program manual of TB control in Egypt, 11-26.

National Tuberculosis Programme (2006): Guideline for management of tuberculosis, National Tuberculosis Control Programme,P5.

National TB program (NTP) (2007): National Control Program. Programmatic management of drug resistant-TB, Egypt, P. 14:28.

National Tuberculosis Programme,(2008):Management of tuberculosis training for health facility staff, Tuberculosis in Egypt, P6.

Neff TA (1986): Bronchoscopy and Bactic for the Diagnosis of TB. Am Rev Respir Dis 133: 962.

Nerlich AG, Haas CJ, Zink A et al. (1997): Molecular evidence of pulmonary tuberculosis in an ancient Egyptian mummy. Lancet; 350 (9088):1404.

Ngo SC; Zimhony O; Chung WJ; Sayahi H; Jacobs WR Jr; Welch JT(2007):Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother. 2007 Jul;51(7):2430-5. Epub 2007 May 7

Norris J.A.D., Whiteman B. and Milburn H.J. (2000): Characteristic of non-compliant patients with tuberculosis. Thorax; 55(Suppl.3): A25p.3.

Oaf F.M., EL-Maraghy M.E., Mahmoud M.F., et al. (1989):Primary drug resistance among newly diagnosed cases with pulmonary tuberculosis . Egypt J. Chest Dis.& Tuberculosis ; 36:137.

Ormerod LP (2005): Multidrug-resistant tuberculosis (MDR-TB): epidemiology, Prevention, and treatment. Br Med Bull; 73-74:17-24

Osman A.H., Abdel Wahab N., Abdel-Aziz and Abdel Magid T.N. (1993): The problem of Rifampicin resistance among tuberculous patients. Egypt .J. Chest Dis. &Tuber; 41-2273.

Pablos-Me´ndez A, Raviglione MC, Laszlo A et al. (1998): Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med; 338 (3):1641–9.

Pai M; and Menzies D (2007):Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?. Clin Infect Dis 2007; 44:74.

Pai M; Riley LW; Colford JM Jr (2004): Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.Lancet Infect Dis 2004 Dec;4(12):761-76.

Pai M; Zwerling A; Menzies D (2008):Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update.Ann Intern Med. 2008 Aug 5;149(3):177-84. Epub 2008 Jun 30.

Palomino JC (2006): Newer Diagnostics for Tuberculosis and Multi-Drug Resistant Tuberculosis. Curr Opin Pulm Med; 12 (3):172-178.

Pearson ML, Jereb JA, Frieden TR et al. (1992): Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann. Intern. Med; 117 (3): 191–6.

Peloquin CA, Berning SE, Huitt GW, et al. (1999): Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med;159:932--934.

Perlman DC, El Sadr WM and Nelson ET (1997): Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immuno-suppression. Clin Infect Dis; 25: 242–46.

Poojary A, Nataraj G, Kanade S et al. (2006): Rapid antibiotic susceptibility testing of Mycobacterium tuberculosis: its utility in resource poor settings. Indian J Med Microbiol; 24 (4):268-72.

Pozzi G, Meloni M, Iona E et al. (1999): rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol; 37 (4): 1197–1199.

Prasad R (2007): Management of MDR-TB: practitioner's view point. Indian Journal of Tuberculosis 54: 3-11.

Quan S, Venter H and Dabbs ER (1997): Ribosylative inactivation of rifampicin by Mycobacterium smegmatis in a principal contributor to its low susceptibility to this antibiotic antimicrob. Agents. Chemother; 41: 2456-60.

Ramchandran R and Paramasivan CN (2002): What is new in the diagnosis of tuberculosis? Part I-techniques for diagnosis of tuberculosis. ICMR Bulletin 32(8): 69-76.

Raynaud C; Laneelle MA; Senaratne RH; et al.,(1999): Mechanisms of pyrazinamide resistance in Mycobacterium tuberculosis: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999 Jun;145 (Pt 6):1359-67

Reported Tuberculosis in the United States(2007): p22.

Reyes-Teran G, Sierra-madero JG, Martinez del Cerro V et al. (1996): Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis; 22: 572-4.

Rose DN, Schechter CB and Adler JJ (1995): Interpretation of the tuberculin skin test. J Gen Intern Med; 10 (11): 635 - 642.

Roth A, Schaberg T and Mauch H (1997): Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J; 10 (8): 1877–1891.

Sander CC (1991): Review of preclinical studies with ofloxacin. Clin Infect Dis; 14: 526--538.

Sayed A (2006): Drug resistance in tuberculosis an essay submitted for partial fulfillment of the master degree in chest disease. Faculty of Medicine, Cairo University.

Schlesinger N, Lardizabal A, Rao J et al. (2005): Tuberculosis of the spine, experience in an inner city hospital. J Clin Rheumatol 11: 17-20.

Sharma R, Saxena D, Dwivedi AK, Misra A. (2001): Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res; 18:1405--1410.

Shenai S, Rodrigues C, and Mehta AP (2002): Evaluation of a New Phage Amplification Technology for Rapid Diagnosis of Tuberculosis. Indian Journal of Medical Microbiology 20(4): 194-199.

Shriner KA, Mathison GE and Goetz MB (1992): Comparison of mycobacterial lymph adenitis among persons infected with HIV and seronegative control. Clin Infect Dis 15: 601.

Siddiqi K, Lambert ML and Walley J (2003): Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis; 3 (5):288–96.

Simone MP and Doooley WS (1995): The phenomenon of multidrug-resistant tuberculosis. Tuberculosis clinical management and new challenges. Rossaman MD, Mac Gregor RR Mc. Grow Hill Inc; 291: 308.

Soini H and Musser JM (2001): Molecular diagnosis of mycobacteria. Clin Chem; 47: 809-14.

Somoskovi A, Kodmon C, Lantos A et al. (2000): Comparison of recoveries of mycobacterium tuberculosis using the automated BACTEC

MGIT 960system, the BACTEC 469 TB system and Lowenstein-Jensen Medium. J of Clin Microbiol 38(6): 2395-2397.

Sreevatsan S., Pan X. and Zhang Y.(1997): Mutations associated by pyrazinamide resistance in Pnc A of mycobacterium tuberculosis organisms .antimicrobial Agents Chemother; 41:636-40

Stanford JL (1997): Fronters in mycobacteriology. Symposium sponsored by national Jewish center for immunology and respiratory Medicine. Vail, Colarado National Jewish center for Immunology and Respiratory Medicine.

Steels M.A., Burke R.F. and Des Prez R.M. (1991): Toxic hepatitis with Isoniazid and Ryampicin. Chest; 99: 465.

Sullwan EA, Krieswirth BN and Palumbo L (1995): Emergence of fluroquinolone resistant tubrculosis in New York City. Lancet 345: 1148-1150.

Tag El Din MA, Zaher H and Naser MA (1998): Epidemiology of tuberculosis. Tuberculosis control guide.

Takiff HE, Salazar L, Guerrero C and Telenti A (1994): Caught from Kamal (2006) Thesis submitted in Ain Shams University (multiple drug resistance tuberculosis in Abbasia Chest Hospital from January 2005 to December 2005).

Takiff H and Heifets L (2002): In search of rapid diagnosis and drug-resistance detection tools: is the FASTPlaqueTB test the answer? Int J Tuberc Lung Dis; 6 (7): 560-

TB Alliance , Accelerating the Pace. (2009): Annual Report of the Global Alliance for TB Drug Development .

Telenti A, Honore N, Bermasconi C (1997): Genotypic assessment of isoniazid and rifampicin resistant in m.tuberculosis a blind study at reference laboratory level. J Clin Microbial; 35: 719-23.

Tenover FC, Growfod JT and Huebner RE (1993): The resurgence of tuberculosis. In your laboratory ready? J Clin Microbiol 31: 767-770.

Timperi, L.L.Han, A. Sloutsky M. C. Becerra, E.A. Nardell, J.J. Salazar, M.C. Smith-Fawzi (2004): massachsetts state laboratory institute, Boston, department of epidemiology, Harvard school of public health, Boston programme in infectious diseases and social change, department of social medicine, Harvard Medical School. Boston USA .INT J TUBERC LUNG DIS 9(2):175-180 (2005).

Tiruvilumala P and Reichman LB (2002): Tuberculosis. Annu Rev Public Health 23: 403-426.

Thwaites G, Chau TT, Mai NT et al. (2000): Tuberculous meningitis. J Neurol Neurosurg Psychiatry; 68 (3): 289–99.

Tortoli E, Cichero P, Piersimoni C et al. (1999): Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: Multicentre study. J Clin Microbiol 37: 3578-3582.

Trapnell C, Narang P, Li R and Lawelle J (1996): Increased plasma rifambutin levels with concomitant fluconazole therapy I HIV-infected patients. Ann Intern Med 24: 573-576.

Vareldzis BP, Grosset J, de Kantor I et al. (1994): Drug-resistant tuberculosis: laboratory issues. World Health Organization Recommendations. Tuber Lung Dis; 75 (1): 1-7.

Von Pirquet C (1990): Frequency of tuberculosis in childhood. JAMA; 52: 675–78.

Wang SX and Tay L (2002): Early identification of Mycobacterium tuberculosis complex in BACTEC cultures by ligase chain reaction. J Med Microbiol; 51 (8):710-2.

Warren and Body AB (1995): Bacteriology and diagnosis in Rossman, MD and MacGregor RR (eds): tuberculosis clinical management and new challenges, 1st edition, New York, McGraw Hill Press Ch. 3, P. 47-52.

Weyer K. (2003): standardized management of MDR-TB in south Africa . session on treatment of TB:new data from clinical trials and demonstration projects . Seattle, WA: AmericanThoracic society 99th international conference.

Wise GJ, and Marella VK (2003): Genitourinary Manifestatiosn of tuberculosis. Clin North Am 30: 111-21.

Woods GL (1998): Mycobacteria in clinical diagnosis and management by laboratory methods. 19th ed. Edited by Johon Bermard Henery (ed) WB sunders company Philadelphia, Pennsylvania, P. 1194: 1209.

Woods GL (2002): The mycobacteriology laboratory and new diagnostic techniques. Infect Dis Clin North Am; 16 (1):127-44.

Woods GL, Fish G, Plaunt M, and Murphy T (1997): Clinical evaluation of difco ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 35: 121-124.

WHO (1994):A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD). Control of tuberculosis transmission in health care settings. Tubercle Lung Dis.;144:745-49.

World Health Organization (WHO) (1998): Global tuberculosis control. WHO report WWW. WHO Int /9 tb/ Publications

World Health Organization (WHO) (2000): ,TUBERCULOSIS (MDR-TB) WHO/CDS/TB/2000.279.

WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance surveillance (2002): Anti-Tuberculosis Drug Resistance in the world: third global report\ the WHO\IUATLD Global project on anti-tuberculosis drug resistance surveillance, 1999-2002.

WHO(2003); TREATMENT OF TUBERCULOSIS: GUIDELINES FOR NATIONAL PROGRAMMES
WHO/CDS/TB/2003.313 THIRD EDITION.

World Health Organization (WHO) (2003a): Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes, 3rd edn. (WHO/CDS/TB/ 2003.13). Geneva: WHO.

World Health Organization (2004): global tuberculosis control. Surveillance, planning, financing. WHOreport2004. Geneva

World Health Organization (WHO) (2004a): Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Document no. (WHO/HTM/TB/2004.343). Geneva: WHO.

World Health Organization (2004b): Global Tuberculosis Control:Surveillance,planning,financing;(WHO/HTM/TB/2004.331).Genev
a: WHO.

WHO report (2005): Global Tuberculosis Control Surveillance, Planning, Financing. World Health Organization Geneva. Switzerland.

World Health Organization (2006a): Guidelines for the programmatic management of drug-resistant tuberculosis;(WHO/HTM/TB/2006.361).Geneva WHO.

World Health Organization (2006b): Strategic Approach for the Strengthening of Laboratory Services for Tuberculosis Control, 2006-2009. (WHO/HTM/TB/2006.364).

World Health Organization (2007a): Global tuberculosis control: surveillance, planning, financing. Tuberculosis country profile of Egypt .http://www.who.int/GlobalAtlas/predefinedReports/TB/PDF_Files/egy.pdf . (WHO/HTM/TB/2007.376). Geneva. WHO.

World Health Organization (2007b): Table 5. Definitions of tuberculosis cases and treatment outcomes. http://www.who.int/tb/publications/global_report/2007/table_5/en/index.html

WHO(2008): WHO report on global tuberculosis control 2008, p10.

WHO/IUATLD(2008): Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, report;No.4.http://www.who.int/tb/features_archive/drsreport_launch_26feb08/en/index.html

Yew WW, Chau CH (1995): Drug-resistant tuberculosis in 1990s. Eur Respir J, 8: 1184-1192.

Yoshiyama T, Ito K, Ogata H et al. (2004): Caught from Abd El Hamid, (2006) Thesis submitted in Ain Shams University (Rapid detection

of multidrug resistant mycobacterium tuberculosis using mycobacteria growth indication tube (MGIT system

Youssef S (1997): Serological diagnosis of pulmonary tuberculosis. Ph.D. Microbiology. Faculty of medicine. Cairo University.

Zhang Y and Telenti A (2000): Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatful GF, Jacobs WR Jr (eds). Molecular Genetics of Mycobacteria. Washington DC: ASM Press; 235–254.

Zhang, Y, Vilcheze, C, Jacobs, WR. (2005): Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Tuberculosis and the tubercle bacillus, Cole, ST, Eisenach, KD, McMurray, DN, Jacobs, WR, (Eds), ASM Press, Washington, DC, 2005.

Zheng X and Roberts GD (1999): Diagnosis and susceptibility testing and nontuberculous mycobacterial infections, 4th ed. Edited by D schoolsberg. Philadelphia WB sounders Co, Chapt 4: 57.

Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA (2001): Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001;21:1037—1045

Zimhony O, Cox JS, Welch JT et al. (2000): Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med; 6 (9):1043-7.

Zink AR, Grabner W, Reischl U et al. (2003): Molecular study on human tuberculosis in three geographically distinct and time delineated populations from ancient Egypt. Epidemiol Infect; 130 (2): 239-49.